Clinical Trial Search

Primary: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort — 99097; 34095 pg/ml — p=<0.001

Primary: Overall Survival — 24.8 Months

Primary: Response Rate — .125 proportion of participants

Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants

Primary: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 4 Participants

Primary: Progression Free Survival With the Combination of GDC-0449 With Gemcitabine and Nab-paclitaxel. — 5.42 months

Primary: Recurrence Free Survival — 15.6 months

Primary: Dose Limiting Toxicities — 0; 0; 1; 3 Participants

Primary: Individually Optimized Contrast-enhanced 4DCT for Radiotherapy Simulation — 4.1; 2.5; 3.6; 3.9 units on a scale

Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants

Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001

Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants

Primary: Disease Control Rate (DCR) at 4 Months Using RECIST 1.1 — 2 Participants

Primary: Tolerability as Measured by Number of Participants With Related Adverse Events — 15; 1; 1; 1 Participants

Primary: 12- Month Overall Survival (OS) — 16 Participants

Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants

Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) — 0; 0 Percent of Participants

Primary: S-MRCP and S-EUS Concordance

Primary: Maximal Tolerated Dose (MTD) & Dose Limiting Toxicity (DLT) of Intratumoral Injections of BC-819 — 0; 1 participants

Primary: Acute Toxicity Rates of Grade 3 or Greater Gastrointestinal and Hematologic Toxicities (as Raw Percentage) — 13.89; 0.00; 2.78; 0.00 percentage of participants

Primary: Disease Control Rate — 25 percentage of participants

Primary: Percent of Patients Experiencing an Unacceptable Toxicity — 6.67; 6.67 Percentage of Participants

Primary: Number of Patients Experiencing a Grade 3 or Above Treatment- Related Toxicity — 1; 5 Participants

Primary: Complete Response Rate — 2; 15; 4; 3 Participants

Primary: Stage 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)…

Primary: Best Overall Response (BOR) — 0; 0; 3; 11 Participants

Primary: Late Gastrointestinal Toxicities — 13 Participants

Primary: Deoxyhemoglobin Concentration (DHb) — .6968475; .3483283; .7021826; .4945491 alpha units — p=0.001

Primary: Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy…

Primary: Number of Patients With Pancreatic Fistula — 9; 8 participants